详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma

5| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China [2]Department of Sports Human Sciences, Hebei Sport University, Shijiazhuang 050041, Hebei, China [3]Second Department of Neurosurgery, Hebei General Hospital, Shijiazhuang 050057, Hebei, China [4]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China [5]Graduate School, Hebei North University, Zhangjiakou 075132, Hebei, China

出处：

DOI：

ISSN：

关键词： Glioma Temozolomide resistance H3K27me3 GSK-J4

摘要：

Temozolomide (TMZ) is the first-line chemotherapeutic agent for malignant glioma, but its resistance limited the benefits of the treated patients. In this study, the role and significance of trimethylation of histone H3 lysine 27 (H3K27me3) in TMZ resistance were investigated. Data from twenty advanced glioma patients were collected, and their pathological samples were analyzed for H3K27me3 levels. TMZ sensitivity was compared between glioma cells U87 and TMZ-resistant cells U87TR, with H3K27me3 levels determined in both cells. The effects of H3K27me3 demethylases inhibitor GSK-J4, combined with TMZ, were assessed on the proliferation and migration of U87TR cells. The results indicated that a high level of H3K27me3 predicts longer disease free survival (DFS) and overall survival (OS) in glioma patients receiving TMZ treatment. The H3K27me3 level was lower in U87TR cells compared to U87 cells. GSK-J4 increased the H3K27me3 level in U87TR cells and decreased their resistance to TMZ. In summary, this study identified a novel marker of TMZ resistance in glioma and provided a new strategy to address this challenge. These findings are significant for improving the clinical treatment of glioma in the future.Copyright © 2024. Published by Elsevier B.V.

基金：

语种：

WOS：

PubmedID：

中科院分区：

出版当年[2025]版：

大类 | 4 区医学

小类 | 4 区神经科学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区神经科学

JCR分区：

出版当年[2023]版：

Q3 NEUROSCIENCES

最新[2023]版：

Q3 NEUROSCIENCES

影响因子： 2.7 最新[2023版] 2.9 最新五年平均 2.7 出版当年[2025版] 2.9 出版当年五年平均 0 出版前一年[2024版]

第一作者：

第一作者机构： [1]Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang 050057, Hebei, China [5]Graduate School, Hebei North University, Zhangjiakou 075132, Hebei, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma [2] Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma [3]LAMB1 downregulation suppresses glioma progression by inhibiting aerobic glycolysis through regulation of the NF-κB/HK2 axis [4]胶质母细胞瘤替莫唑胺耐药的共表达网络分析 [5]骨肉瘤细胞和组织H3K27me3表达与临床病理特征相关性研究 [6]H3K27me3 and VEGF is associated with poor prognosis in patients with synovial sarcoma [7]microRNA-143-3p在脑胶质瘤中的表达及其作用 [8]Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients [9]EZH2和H3K27me3在食管鳞状细胞癌中的表达及意义 [10]Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines.